StockData
Amgen Inc logo

Amgen Inc (AMGN) income statement

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Amgen Inc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
70.9%
Operating margin
32.4%
Net margin
24.1%
Return on equity, FY2025
106.1%

Financial strength

Current ratio
1.48
Debt to equity
3.76
Debt to assets
56.2%
Cash to current liabilities
56.8%

Valuation

P/E ratio
25.7
Price to sales
6.17
Price to book
16.72
Dividend yield
2.18%

See a number that looks wrong?